Evaluation of Antiretroviral Therapy Initiated Among Pregnant Women Under Option B+ by Viral Load and CD4 Count Outcomes in Selected Hospitals of West Shewa Zone, Oromia Region, Ethiopia

References

• Frank TD, Carter A, Jahagirdar D, et al. Global, regional, and national incidence, prevalence, and mortality of HIV, 1980–2017, and forecasts to 2030, for 195 countries and territories: a systematic analysis for the global burden of diseases, injuries, and risk factors study 2017. Lancet HIV. 2019;6(12):e831–e859. doi:10.1016/S2352-3018(19)30196-131439534
   PubMed Web of Science ®Google Scholar
• Joint United Nations Programme on HIV/AIDS. Global report: UNAIDS report on the global AIDS epidemic 2013. Geneva: Joint United Nations Programme on HIV/AIDS; 2013.
   Google Scholar
• Gopalappa C, Stover J, Shaffer N, Mahy M. The costs and benefits of Option B+ for the prevention of mother-to-child transmission of HIV. AIDS. 2014;28:S5–14. doi:10.1097/QAD.000000000000008324468947
   PubMed Web of Science ®Google Scholar
• Fasawe O, Avila C, Shaffer N, et al. Cost-effectiveness analysis of Option B+ for HIV prevention and treatment of mothers and children in Malawi. PLoS One. 2013;8(3):e57778. doi:10.1371/journal.pone.005777823554867
   PubMed Web of Science ®Google Scholar
• Aizire J. G Fowler M, M Coovadia H. Operational Issues and Barriers to Implementation of Prevention of Mother-To-Child Transmission of HIV (PMTCT) Interventions in Sub-Saharan Africa. Curr HIV Res. 2013;11(2):144–159.
   Google Scholar
• Scott CA, Iyer HS, Bwalya DL, et al. Uptake, outcomes, and costs of antenatal, well-baby, and prevention of mother-to-child transmission of HIV services under routine care conditions in Zambia. PLoS One. 2013;8(8):e72444. doi:10.1371/journal.pone.007244424015245
   PubMedGoogle Scholar
• Gourlay A, Birdthistle I, Mburu G, Iorpenda K, Wringe A. Barriers and facilitating factors to the uptake of antiretroviral drugs for prevention of mother‐to‐child transmission of HIV in sub‐Saharan Africa: a systematic review. J Int AIDS Soc. 2013;16(1):18588. doi:10.7448/IAS.16.1.1858823870277
   PubMed Web of Science ®Google Scholar
• Mitiku I, Arefayne M, Mesfin Y, Gizaw M. Factors associated with loss to follow‐up among women in Option B+ PMTCT programme in northeast Ethiopia: a retrospective cohort study. J Int AIDS Soc. 2016;19(1):20662. doi:10.7448/IAS.19.1.2066227005750
   PubMedGoogle Scholar
• Gill MM, Hoffman HJ, Bobrow EA, et al. Detectable viral load in late pregnancy among women in the Rwanda option B+ PMTCT program: enrollment results from the Kabeho study. PLoS One. 2016;11(12):e0168671. doi:10.1371/journal.pone.016867128006001
   PubMedGoogle Scholar
• Myrtil MP, Puttkammer N, Gloyd S, et al. ART attrition across health facilities implementing Option B+ in Haiti. J Int Assoc Provid AIDS Care (JIAPAC). 2018;17:2325958218774037. doi:10.1177/232595821877403729781378
   PubMedGoogle Scholar
• Haas AD, Tenthani L, Msukwa MT, et al. Retention in care during the first 3 years of antiretroviral therapy for women in Malawi’s option B+ programme: an observational cohort study. Lancet HIV. 2016;3(4):e175–82. doi:10.1016/S2352-3018(16)00008-427036993
   PubMed Web of Science ®Google Scholar
• Kamuyango AA, Hirschhorn LR, Wang W, Jansen P, Hoffman RM. One-year outcomes of women started on antiretroviral therapy during pregnancy before and after the implementation of Option B+ in Malawi: a retrospective chart review. World J AIDS. 2014;4(3):332. doi:10.4236/wja.2014.4303925774326
   PubMedGoogle Scholar
• Ayanga RA, Namukwaya Z, Lugoloobi EN, et al. Virological Response Among HIV-Infected Pregnant and Lactating Women Initiated on Option B + Attending the PMTCT Program at Mulago National Hospital. Kampala, Uganda: International AIDS Society; 2015.
   Google Scholar
• Seyoum A, Ndlovu P, Temesgen Z. Joint longitudinal data analysis in detecting determinants of CD4 cell count change and adherence to highly active antiretroviral therapy at Felege Hiwot teaching and specialized Hospital, North-west Ethiopia (Amhara Region). AIDS Res Ther. 2017;14(1):14. doi:10.1186/s12981-017-0141-328302125
   PubMedGoogle Scholar
• Maskew M, Brennan AT, Westreich D, McNamara L, MacPhail AP, Fox MP. Gender differences in mortality and CD4 count response among virally suppressed HIV-positive patients. J Womens Health. 2013;22(2):113–120. doi:10.1089/jwh.2012.3585
   PubMed Web of Science ®Google Scholar
• Ngarina M, Tarimo EA, Naburi H, et al. Women’s preferences regarding infant or maternal antiretroviral prophylaxis for prevention of mother-to-child transmission of HIV during breastfeeding and their views on Option B+ in Dar es Salaam, Tanzania. PLoS One. 2014;9(1):e85310. doi:10.1371/journal.pone.008531024465532
   PubMed Web of Science ®Google Scholar
• Nachega JB, Mugavero MJ, Zeier M, Vitória M, Gallant JE. Treatment simplification in HIV-infected adults as a strategy to prevent toxicity, improve adherence, quality of life and decrease healthcare costs. Patient Prefer Adherence. 2011;5:357. doi:10.2147/PPA.S2277121845035
   PubMed Web of Science ®Google Scholar
• Tsegaye D, Deribe L, Wodajo S. Level of Adherence and Associated Factors to Option B+ PMTCT Among Pregnant and Lactating Mothers in Selected Government Health Facilities of South Wollo Zone. Amhara Region, North East Ethiopia; 2016.
   Google Scholar
• Teshome W, Assefa A. Predictors of immunological failure of antiretroviral therapy among HIV infected patients in Ethiopia: a matched case-control study. PLoS One. 2014;9(12):e115125. doi:10.1371/journal.pone.011512525536416
   PubMedGoogle Scholar
• Ijigu GM, Gemeda DH, Angamo MT. Maternal immunologic and clinical response to antiretroviral therapy initiation before or during pregnancy in HIV-1 infected women and associated factors in Southwest Ethiopia. Gulhane Med J. 2015;57(2). doi:10.5455/gulhane.155305
   Google Scholar